Semax vs Selank

Semax and Selank are two research peptides that are frequently grouped together because both emerged from the same line of Russian peptide research and both appear in cognitive, stress, and neuroprotection studies — but they are structurally distinct, derive from different parent molecules, and are characterized through different documented mechanisms. Semax is a synthetic peptide based on a fragment of the hormone ACTH (adrenocorticotropic hormone), and its preclinical literature centers on neurotrophin regulation and protection of brain tissue in cerebral-ischemia models. Selank is a synthetic peptide based on the immunopeptide tuftsin, and its research is concentrated on anxiety and stress models, inhibitory synaptic activity, and immune/inflammation gene expression. The comparison below summarizes what published research models actually show for each compound, where their mechanisms diverge, and — importantly — the limits of that evidence, which is heavily preclinical and, on the human side, drawn almost entirely from small, Russian-published studies that have not been independently replicated.

What are Semax and Selank?

Semax is a short synthetic peptide built around the ACTH(4–10) sequence — that is, a fragment of adrenocorticotropic hormone — extended with a Pro-Gly-Pro tail that improves its stability. In the research literature it is most often described as a peptide with reported effects on learning and memory in animals and a protective profile in models of reduced brain blood flow. It is produced synthetically for laboratory research and is most commonly studied after intranasal administration in rodents.

Selank is a short synthetic peptide based on tuftsin, a naturally occurring immunomodulatory tetrapeptide, again extended with a Pro-Gly-Pro sequence for stability. Because of its tuftsin parentage, Selank carries research interest on two fronts at once: an immune/inflammatory line inherited from tuftsin biology, and a behavioral line concerned with anxiety and stress responses in rodents. Like Semax, it is produced synthetically and is most often studied after intranasal dosing in animal models. The two peptides are not related to each other by sequence: Semax descends from a pituitary hormone fragment, Selank from an immunopeptide, and treating them as interchangeable is a common error in non-scientific summaries.

How Semax is studied: mechanism

The mechanistic research on Semax is concentrated on the regulation of neurotrophins — signaling proteins that support the survival and function of neurons — with brain-derived neurotrophic factor (BDNF) the most consistently reported target. In a rat study, a single dose of Semax was reported to raise hippocampal BDNF protein roughly 1.4-fold and to enhance activation of its receptor trkB, changes the authors associated with improved conditioned-avoidance learning.¹ Related work reported that Semax binds specifically to membranes of the rat basal forebrain in a calcium-dependent manner and raised BDNF protein in that region after intranasal dosing, indicating a defined molecular interaction rather than a diffuse effect.²

This BDNF effect is not confined to a single brain region. Intranasal Semax was reported to increase BDNF expression across multiple areas of the rat brain in vivo.³ A more detailed time-course study compared the dynamics of nerve growth factor (NGF) and BDNF gene expression in the hippocampus, frontal cortex, and retina under Semax action, and reported that the activation was both region-specific and time-dependent — in other words, the peptide does not simply switch neurotrophin genes on uniformly, but shifts their expression in a patterned way across tissue and time.⁴

The second major mechanistic thread for Semax is neuroprotection in models of cerebral ischemia — reduced or interrupted blood flow to the brain. In a rat model of incomplete global ischemia, Semax was reported to blunt the ischemia-induced rise in nitric oxide generation in the cerebral cortex and to improve neurologic function, an effect not produced by glycine used as a comparator.⁵ After focal ischemia (a middle-cerebral-artery occlusion model), Semax was reported to selectively up-regulate the transcription of neurotrophins and their receptor genes in the cortex.⁶ A genome-wide transcriptional analysis in the same focal-ischemia setting reported that the immune response was the gene category most strongly modulated by Semax after stroke, with vascular-development genes also affected.⁷ A separate brain-protein-expression study in a rat cerebral ischemia-reperfusion model reported that Semax suppressed inflammatory markers (including MMP-9, c-Fos, and JNK) and activated the CREB signaling pathway.⁸ Taken together, the preclinical picture for Semax is one of a peptide studied for neurotrophin up-regulation and for anti-inflammatory, anti-ischemic gene-expression changes in injured brain tissue.

How Selank is studied: mechanism

Selank’s mechanistic literature overlaps with Semax’s at one point — both peptides are reported to modulate BDNF — but otherwise follows a different path. Intranasal Selank was reported to regulate BDNF expression in the rat hippocampus in vivo.⁹ In a behavioral-mechanistic study, Selank was reported to protect against ethanol-induced memory impairment in rats, with the authors linking that cognitive effect to BDNF content in the hippocampus and prefrontal cortex.¹⁰

Where Selank’s mechanism most clearly diverges from Semax’s is in its reported effects on inhibitory neurotransmission. In a brain-slice electrophysiology study, Selank increased the amplitude and frequency of inhibitory postsynaptic currents in CA1 pyramidal neurons of the rat hippocampus — a direct, measurable shift toward greater inhibitory synaptic activity.¹¹ That inhibitory, GABA-associated direction is the throughline of Selank’s anxiety and stress research. A study using a human neuroblastoma cell line (IMR-32) reported that Selank on its own had little effect on the expression of genes involved in GABAergic neurotransmission, but acted as a modulator when combined with other agents — a finding that tempers any simple claim that Selank is a straightforward GABAergic compound.¹²

The third mechanistic thread for Selank is the one inherited from its tuftsin parentage: immune and inflammation gene expression. A study of the temporary dynamics of inflammation-related gene expression reported that Selank, and a Gly-Pro fragment of it, altered the messenger RNA levels of several immune and inflammation genes (including C3, Casp1, Il2rg, and Xcr1) in the rat spleen.¹³ Finally, in a behavioral model, Selank reduced anxiety-associated behavior on its own and enhanced the anxiety-reducing effect of a benzodiazepine under conditions of unpredictable chronic mild stress in rats.¹⁴ The preclinical picture for Selank, then, is one of a peptide studied for inhibitory synaptic effects, anxiety/stress behavior, and immune gene expression — with BDNF modulation as a shared point of contact with Semax.

Where the mechanisms diverge

The most useful way to compare Semax and Selank is by mechanism and by the research models in which each has been characterized, because their superficial similarity — both are short, Pro-Gly-Pro-stabilized peptides studied for brain-related effects — conceals genuinely different research profiles.

In short: Semax is studied primarily as a peptide that shifts the neurotrophic and inflammatory signaling environment of brain tissue — especially injured or ischemic tissue — while Selank is studied primarily as a peptide that influences inhibitory synaptic activity and immune gene expression, with anxiety and stress behavior as its dominant behavioral readout. The two literatures touch at BDNF modulation in the hippocampus, but they reach that point from different directions and are otherwise concerned with different questions. For a fuller treatment of each peptide on its own, see the dedicated Semax research page and the Selank research page.

The state of the evidence

This is the most important section of any honest comparison, and with Semax and Selank it is also the section most often glossed over. Two facts about the published record matter more than any individual finding above.

First, the evidence is predominantly preclinical. For both peptides, the bulk of the published literature consists of in-vitro experiments, brain-slice electrophysiology, and rodent studies. The neurotrophin, gene-expression, electrophysiology, and behavioral findings cited in the mechanism sections above are all animal or molecular work. Preclinical findings of this kind establish biological plausibility and identify mechanisms worth studying further; they do not establish that an effect will occur, or be beneficial, in a human or in any specific application.

Second, the literature is heavily Russian-published and is dominated by a small number of research groups. Semax and Selank were developed in Russia, and the great majority of their primary literature — including the human studies — was produced and published there, often in Russian-language journals. The two human studies relevant to this comparison illustrate the point. For Semax, a Russian-published clinical study reported raised plasma BDNF and accelerated motor and functional recovery in patients at different stages of ischemic stroke.¹⁵ For Selank, a Russian-published clinical study compared its anxiety-reducing effect and tolerability against a benzodiazepine comparator in patients with anxiety disorders and reported an anxiety-reducing effect along with mild effects on attention and cognition that persisted about a week after treatment.¹⁶

It is essential to read those two human reports for exactly what they are. They are small clinical studies, published within a single national research tradition, that have not been independently replicated by research groups elsewhere using comparable methods. That is not a footnote — it is central to interpreting the peptides. Independent, large-scale, randomized controlled trials are lacking for both Semax and Selank. Until such replication exists, the human evidence for both peptides should be treated as preliminary rather than established.

So the accurate summary is this: Semax and Selank are research peptides whose cognitive-, stress-, and neuroprotection-associated effects are documented mainly in animal and molecular models, with a thin layer of small, unreplicated, Russian-published human studies on top. Any comparison of their relative usefulness for a real-world application is, at present, not answerable from the published record.

How researchers approach comparing them

Because Semax and Selank are mechanistically distinct and have not been extensively tested side by side in the same model, researchers designing comparative work generally treat them as different tools selected for different questions rather than as ranked alternatives. A protocol interested in neurotrophin regulation, cortical gene expression after ischemia, or neuroprotection in a stroke model has a clear rationale for selecting Semax. A protocol interested in inhibitory synaptic activity, anxiety and chronic-stress behavior, or immune/inflammation gene expression has a clear rationale for selecting Selank. The choice in a research design follows the mechanism under investigation, not a claim that one peptide is universally “stronger” than the other — a framing the evidence does not support, and which is further undermined by the absence of head-to-head human data.

For laboratories sourcing either peptide, the relevant practical questions are identity and purity rather than comparative potency. Both peptides should be obtained with a batch-specific Certificate of Analysis; our guide on how to read a peptide COA explains what to check on that document and why each section matters. A broader view of the research-peptide categories these compounds belong to is available in the research library.

What this does not mean

This article compares two research compounds at the level of documented mechanism and published model systems. It is not medical, veterinary, or scientific advice, and nothing here describes or recommends use in humans or animals. The studies cited are preclinical except where a human clinical study is explicitly identified, and those human studies are small and Russian-published, and have not been independently replicated — they are preliminary findings, not demonstrations of effectiveness for any condition. Semax and Selank are sold strictly as research chemicals for in-vitro laboratory research. They are not drugs, supplements, or foods; they are not approved for human or animal use; and they are not intended to diagnose, treat, cure, or prevent any condition.

Frequently asked questions

Are Semax and Selank the same type of peptide?

No. They are structurally distinct and derive from different parent molecules. Semax is an analog of ACTH(4–10), a fragment of adrenocorticotropic hormone. Selank is an analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Both are short synthetic peptides studied for brain-related effects, and both share a Pro-Gly-Pro stabilizing sequence, but they do not share a parent molecule or a primary mechanism.

What is the main mechanistic difference between them?

Semax is studied primarily for up-regulation of neurotrophins — especially BDNF — and for anti-inflammatory, anti-ischemic gene-expression changes in brain tissue, particularly in cerebral-ischemia models. Selank is studied primarily for effects on inhibitory (GABA-associated) synaptic activity, anxiety and stress behavior, and immune/inflammation gene expression. The two literatures overlap at one point: both peptides are reported to modulate BDNF in the hippocampus.

Is there human research on either peptide?

Limited human research exists for both, but it must be read carefully. For Semax, a Russian-published clinical study reported raised plasma BDNF and accelerated recovery in ischemic-stroke patients. For Selank, a Russian-published clinical study reported an anxiety-reducing effect and mild cognitive effects in patients with anxiety disorders. Both are small studies from a single national research tradition and have not been independently replicated; they are preliminary findings, not established results.

Why is the literature on these peptides so heavily Russian-published?

Semax and Selank were both developed in Russia, and the great majority of their primary research — preclinical and clinical — has been produced and published by Russian research groups, often in Russian-language journals. A practical consequence is that the human data in particular has not been replicated by independent groups elsewhere, so it should be treated as preliminary.

Which one is “better” for cognitive research?

The published research does not answer that question. Semax and Selank have largely been characterized in different research models — Semax in neurotrophin and cerebral-ischemia models, Selank in anxiety, stress, and electrophysiology models — head-to-head studies are uncommon, and the human data for both is small and unreplicated. Framing one as universally superior is not supported by the evidence.

Do both peptides affect BDNF?

Both are reported to modulate BDNF expression in the hippocampus, which is the clearest point of overlap between their literatures. For Semax, BDNF up-regulation is the central and most consistently reported mechanistic thread. For Selank, BDNF modulation is one thread among several, alongside inhibitory synaptic effects and immune gene expression. Sharing a reported effect on BDNF does not make the two peptides mechanistically equivalent.

What should a laboratory check before sourcing either peptide?

Identity and purity, documented on a batch-specific Certificate of Analysis: an HPLC purity result with a chromatogram, and a mass-spectrometry result confirming molecular identity, both tied to the lot number on the vial. Our COA guide walks through each section of that document.

References

1. Dolotov OV, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006. PMID 16996037
2. Dolotov OV, et al. Semax, an analog of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain. J Neurochem. 2006. PMID 16635254
3. Dolotov OV, et al. The heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain in vivo. Dokl Biol Sci. 2003. PMID 14556513
4. Shadrina M, et al. Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action. J Mol Neurosci. 2010. PMID 19662538
5. Bashkatova VG, et al. Novel synthetic analogue of ACTH 4-10 (Semax) but not glycine prevents the enhanced nitric oxide generation in cerebral cortex of rats with incomplete global ischemia. Brain Res. 2001. PMID 11245825
6. Dmitrieva VG, et al. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010. PMID 19633950
7. Medvedeva EV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014. PMID 24661604
8. Sudarkina OY, et al. Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion. Int J Mol Sci. 2021. PMID 34201112
9. Inozemtseva LS, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008. PMID 18841804
10. Kolik LG, et al. Selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating of BDNF content in the hippocampus and prefrontal cortex in rats. Bull Exp Biol Med. 2019. PMID 31625062
11. Povarov IS, et al. Effect of Selank on spontaneous synaptic activity of rat hippocampal CA1 neurons. Bull Exp Biol Med. 2017. PMID 28361410
12. Filatova E, et al. GABA, Selank, and olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. Front Pharmacol. 2017. PMID 28293190
13. Kolomin T, et al. The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Mol Immunol. 2014. PMID 24291245
14. Kasian A, et al. Peptide Selank enhances the effect of diazepam in reducing anxiety in unpredictable chronic mild stress conditions in rats. Behav Neurol. 2017. PMID 28280289
15. Gusev EI, et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PMID 29798983
16. Medvedev VE, et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014. PMID 25176261

Continue

• Semax research overview
• Selank research overview
• How to read a peptide COA
• Research Library
• Research peptides shop

Research Use Only. This page is an educational research comparison for laboratory and scientific context, and is not medical advice. The compounds described are sold strictly as research chemicals for in-vitro laboratory research. They are not drugs, supplements, or foods, and are not intended for human or animal consumption, diagnosis, treatment, or to prevent any condition.